Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

Key Points

• Access to GLP-1 receptor agonists for weight loss varies significantly between the US and three other countries.
• In a comparative analysis, disparities in costs and prescription rates highlight unequal access across the four regions.
• Evaluation of glucagon-like peptide 1 (GLP-1) treatment reveals important differences in utilization trends and healthcare policies across nations in 2023.  The implications of these disparities may affect patient outcomes and treatment accessibility.